NCT04169074 2026-01-14
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
University of Arizona
Phase 2 Terminated
Clinical Trials
8 trialsNCT03979508 2025-11-12
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
Mayo Clinic
Phase 2 Terminated
NCT04227327 2025-07-29
HERMIONE-7
University of Milano Bicocca
Phase 2 Terminated
NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04534283 2024-08-07
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
Indiana University
Phase 2 Terminated
NCT03997448 2024-02-20
Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149
Big Ten Cancer Research Consortium
Phase 2 Terminated
NCT04305236 2023-06-06
Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer
University of California, Irvine
Phase 2 Terminated
NCT03781960 2022-12-14
Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
Abramson Cancer Center at Penn Medicine
Phase 2 Terminated